Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07435454RecruitingPhase 2
Oral paclitaxel plus radiation for advanced esophageal cancer
This trial tests a combination of an oral chemotherapy drug (paclitaxel) and radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. It may be an option if you are 70 or older or cannot tolerate IV chemotherapy and have trouble swallowing.
Nanjing, JiangsuAges 70 years+ - NCT07436845Recruiting
Emotion and treatment for advanced liver cancer
This trial studies if emotional health affects how well targeted therapy and immunotherapy work for people with advanced liver cancer. You will receive chemotherapy directly into the liver along with targeted drugs and immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07448727Recruiting
Early PET scan for head and neck cancer on immunotherapy
This trial uses a special PET/CT scan early in treatment to see if first-line immunotherapy is working for people with recurrent or metastatic head and neck cancer. It aims to learn if early response can predict outcomes and help guide care.
Rome, ItalyAges 18 years+ - NCT07452432Recruiting
Study of chemo before surgery for aggressive kidney/ureter cancer
This study tests whether giving chemotherapy before surgery can help patients with high-grade upper tract cancer that hasn't spread. It aims to find better ways to treat this aggressive cancer.
SeoulAges 19 years+ - NCT07455032RecruitingPhase 1
Neoadjuvant therapy combo for head and neck cancer
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07463573RecruitingPhase 3
New drug vs chemotherapy for advanced esophageal cancer
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07465276RecruitingPhase 2
Two immunotherapies before surgery for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07469319Recruiting
Liver cancer screening for people with cirrhosis
This study tests whether offering an ultrasound and a blood test (alpha-fetoprotein) every 6 months can help find liver cancer early in people with cirrhosis (scarred liver) caused by conditions other than hepatitis B or C. The goal is to reduce deaths from liver cancer in this group.
Aarhus, Central JutlandAges 40–79 - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT07473518Recruiting
Thyroid cancer after childhood radiation therapy
This study looks at thyroid cancer in people who had radiation therapy as children, comparing them to people who did not have radiation. The goal is to see how often thyroid cancer develops after childhood radiation.
BolognaAges 10–43 - NCT07475780Recruiting
Radiofrequency ablation for recurrent parathyroid cancer
This study tests radiofrequency ablation (a heat-based treatment) for parathyroid cancer that has returned after surgery. It's for people who cannot or choose not to have more surgery, and the tumor can be reached with a needle through the skin.
Houston, TexasAges 18 years+ - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT07483307RecruitingPhase 2
Hormone therapy before surgery for lobular breast cancer
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
Basking Ridge, New JerseyAges 50 years+ - NCT07485296RecruitingPhase 2
Postbiotics with pembrolizumab for advanced head and neck cancer
This trial tests whether adding postbiotics (beneficial bacteria byproducts) to the standard immunotherapy drug pembrolizumab can improve your immune system's response against advanced or metastatic head and neck squamous cell carcinoma.
Rozzano, MilanoAges 18 years+ - NCT07532902RecruitingPhase 1
Testing an experimental drug with standard care for solid tumors
This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.
Basking Ridge, New JerseyAges 18 years+ - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT07493668RecruitingPhase 2
Fostrox plus Lenvatinib for advanced liver cancer after immunotherapy
This trial tests whether adding the drug Fostrox to the standard drug Lenvatinib works better than Lenvatinib alone for people with advanced liver cancer that has worsened after initial immunotherapy treatment. It is for those who cannot have surgery and have not had more than one prior cancer treatment.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07509333Recruiting
Team-based treatment plan for older lung cancer patients
This trial is for older adults (60–90) with any stage of the two most common types of lung cancer (NSCLC or SCLC). It uses a team of experts to create a personalized treatment plan and closely monitors your health and quality of life.
Chengdu, SichuanAges 60–70
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,181 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.